On Air Now

Upcoming Shows

Program Schedule »

Tune in to Listen

1440 AM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
80° Feels Like: 84°
Wind: SSW 8 mph Past 24 hrs - Precip: 0.15”
Current Radar for Zip

Today

Scattered Thunderstorms 83°

Tonight

Scattered Thunderstorms 68°

Tomorrow

Thunderstorms 75°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

FDA OKs new generation Boston Scientific heart pacing devices

A view shows the U.S. Food and Drug Administration (FDA) logo at the lobby of its headquarters in Silver Spring, Maryland August 14, 2012. P
A view shows the U.S. Food and Drug Administration (FDA) logo at the lobby of its headquarters in Silver Spring, Maryland August 14, 2012. P

(Reuters) - U.S. health regulators have approved four Boston Scientific Corp implantable devices for heart patients, including a next generation of smaller defibrillators to treat abnormal heart rhythms, the company said on Tuesday.

The Food and Drug Administration approved for sale the Dynagen Mini and Inogen Mini ICDs and the Dynagen X4 and Inogen X4 CRT-Ds, Boston Scientific said.

The Mini ICDs are up to 20 percent smaller by volume and up to 24 percent thinner than rival devices from other companies, Boston Scientific said. Implantable cardioverter defibrillators treat arrhythmias by shocking a dangerously racing heartbeat back into normal rhythms.

"The tiny size of the Mini ICD provides a real benefit to some patients, in particular those with a smaller frame," Dr. Hans-Joachim Trappe from University Marien Hospital Herne, Hospital of Ruhr-University, Bochum, Germany, said in a statement.

The CRT-Ds, or cardiac resynchronization therapy defibrillators, are also used to protect against sudden cardiac death due to abnormal heart rhythms in patients suffering from heart failure, in which the heart is unable to pump blood sufficiently.

Boston Scientific shares rose to $13.45 in extended trading on Tuesday from a New York Stock Exchange close of $13.35.

(Reporting by Bill Berkrot; Editing by Peter Galloway)

Comments